TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.

Also called NCT03354663

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 156 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03354663
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Germany, Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03354663. Allocation not applicable; no masking; primary purpose treatment. Start 2017-12-11 (actual); primary completion 2018-08-02 (actual). Results posted on 2019-08-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation
Acronym
TactiSense
Condition
Paroxysmal Atrial Fibrillation
Intervention (Device)
TactiCath SE
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct03354663
Content hash
e30a990e101c916736d76c19bf52ef20122a8893d1df1dfe3ed137e3bee8d08d